Simplement Spółka z Ograniczoną Odpowiedzialnością Spółka Komandytowa (KRS 0000380435, NIP 1182062319) is a Polish company, headquartered in Janów, Mazowieckie voivodeship. Simplement Spółka z Ograniczoną Odpowiedzialnością operates in: Research and experimental development on biotechnology (PKD 72.11.Z). Industry: Research and development. The company has been listed in the National Court Register since March 15, 2011. Simplement Spółka z Ograniczoną Odpowiedzialnością's most recently reported net revenue was 0 PLN for 2025.
Negative equity
Negative equity in 3 of 4 available reporting years.
No arrears identified in the analysed sources
No arrears or bankruptcy proceedings identified in the analysed sources.
Business profile - Simplement
Identity
- Name
- Simplement Spółka z Ograniczoną Odpowiedzialnością Spółka Komandytowa
- Legal form
- Limited Partnership (Sp.k.)
- Founded
- March 15, 2011
- Registry status as of
- July 15, 2026
- Latest entry
- July 15, 2026
- Founding act
- UMOWA SPÓŁKI KOMANDYTOWEJ ZAWARTA DNIA 20.01.2011 R. PRZED ASESOREM NOTARIALNYM DAGMARĄ KONOPKĄ, ZASTĘPCĄ NOTARIUSZA WIK…
Articles of association history (2)
- January 20, 2011: UMOWA SPÓŁKI KOMANDYTOWEJ ZAWARTA DNIA 20.01.2011 R. PRZED ASESOREM NOTARIALNYM DAGMARĄ KONOPKĄ, ZASTĘPCĄ NOTARIUSZA WIKTORA WĄGRODZKIEGO, KANCELARIA NOTARIALNA W WARSZAWIE, REP. A NR 1243/2011
- November 25, 2014: 25.11.2014 R., PRZED NOTARIUSZEM MAŁGORZATĄ TOMCZYK-PERŁOWSKĄ PROWADZĄCĄ KANCELARIĘ NOTARIALNĄ W BABICACH NOWYCH (BABICE NOWE, UL. WARSZAWSKA 189,05-082 STARE BABICE) REP. A NR 2174/2014. ZMIENIONO § 2.1, § 2.2, § 3.
Activities
General codes (divisions and groups)
General codes indicate a PKD division or group without a specific subclass.
Address and contact
- Address
- UL. WŁADYSŁAWA SIKORSKIEGO, 74, 05-082, JANÓW, POLSKA
- Voivodeship
- MAZOWIECKIE
- District
- WARSZAWSKI ZACHODNI
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- Not disclosed in the registry
Operational status - Simplement
Founded
March 15, 2011
15 years in operation
Legal form
Limited Partnership (Sp.k.)
Registry: RejP
Headquarters
JANÓW
MAZOWIECKIE
Primary PKD
72.11.Z
Research and experimental development on biotechnology
Shareholders
2
shareholders
Filed years
4 years
2019–2025 · profitable: 1/4
Registry entries
30
latest: July 15, 2026
Risk signals
Revenue
0 PLN
2025
Net profit
-2.6 K PLN
2025
Assets
3.3 M PLN
2025
Equity
-757.4 K PLN
2025
EBITDA
-2.6 K PLN
2025
Valuation
1.3 M PLN
Low confidence
Low confidence
Risk and payment profile - Simplement
Credibility rating
45.9 / 100
Average credibility
Insolvency risk
Low
Elevated threat
Closure risk
32
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organisational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
0
0/15 yrs
Board changes
0
0/15 yrs
PKD changes
1
1/15 yrs
Name changes
1
1/15 yrs
Data from 15 years of registry activity.
Credibility history
Payment reliability score from 2019–2025
Current: D (46/100)
Trend: improving (+9.3 pts/year)
Słaba wiarygodność płatnicza – wskaźniki finansowe sugerują podwyższone ryzyko opóźnień lub niewykonania zobowiązań.
Trade credit limit history
Standard limit from 2019–2025
Current: 503.5 K PLN
Safe: 151.1 K PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Directories and rankings for this location
Related articles
Explainer
Mabion in 2026: Polish monoclonal-antibody maker, mWIG40 issuer from Konstantynów Łódzki, Novavax COVID-19 antigen contract
Mabion S.A. (KRS 0000340462), headquartered at ul. Gen. Mariana Langiewicza 60 in Konstantynów Łódzki, is a Polish biotech specialising in monoclonal-antibody production (key project: MabionCD20, a rituximab biosimilar) and in CDMO (Contract Development and Manufacturing Organization) work. Its main international contract is manufacturing the COVID-19 vaccine antigen for Novavax. Founded in 2007 by Maciej Wieczorek and listed on the WSE since 2010, the company is an mWIG40 constituent, with a three-member management board and a five-member supervisory board.
Explainer
Ryvu Therapeutics in 2026: a Kraków oncology biotech, RVU120 in Phase II clinical trials, a six-member management board, an mWIG40 issuer after the Selvita spin-off
Ryvu Therapeutics S.A. (KRS 0000367359), headquartered at ul. Leona Henryka Sternbacha 2 in Kraków, is a Polish oncology biotech developing anti-cancer small-molecule drugs. It has operated as a stand-alone company since the 2019 spin-off from Selvita (which retained the R&D-services business). Flagship project: RVU120 – a CDK8/19 kinase inhibitor in Phase II trials across multiple oncological indications. Listed on the WSE since 2019 and an mWIG40 constituent, with a six-member management board and a seven-member supervisory board.